• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在使用一组耐环丙沙星临床分离株进行挑战研究后,对克林沙星(CI-960、AM-1091、PD127371)和氟罗沙星(Ro 23-6240、AM-833)的纸片扩散药敏试验标准的修改。

Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.

作者信息

Jones R N, Johnson D M

机构信息

Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.

出版信息

Diagn Microbiol Infect Dis. 1995 Apr;21(4):209-13. doi: 10.1016/0732-8893(94)00061-z.

DOI:10.1016/0732-8893(94)00061-z
PMID:7554803
Abstract

A collection of ciprofloxacin-resistant organisms (200 strains) was developed among 300 total test strains to "challenge" the initial interpretive criteria developed for clinafloxacin (formerly CI-960), fleroxacin (formerly Ro 23-6240, AM-833), and ciprofloxacin. Generated results indicate the necessity for modified criteria for disk diffusion tests (5-micrograms disks) as follows: for clinafloxacin, susceptible at > or = 21 mm ( < or = 1 microgram/ml) and resistant at < or = 17 mm ( > or = 4 micrograms/ml), or susceptible at > or = 19 mm ( < or = 2 micrograms/liter) and resistant at < or = 15 mm ( > or = 8 micrograms/ml); for fleroxacin, susceptible at > or = 16 mm ( < or = 2 micrograms/ml) and resistant at < or = 11 mm ( > or = 8 micrograms/ml); and for ciprofloxacin, resistant at < or = 17 mm > or = 4 micrograms/ml). These modifications maximize total absolute interpretive accuracy between the standardized test methods, especially minimizing the potential for false susceptibility (very major errors) when testing truly resistant isolates. The clinafloxacin spectrum was widest against these resistant isolates, and the other two tested fluoroquinolones (ciprofloxacin, fleroxacin) possessed comparable overall spectrums of activity, although ciprofloxacin was generally more active on a weight basis. We urge the rapid acceptance of these criteria to improve the accuracy of the widely used National Committee for Clinical Laboratory Standards method for disk diffusion tests.

摘要

在300株受试菌株中培养出一组耐环丙沙星的菌株(200株),以“检验”为克林沙星(原CI-960)、氟罗沙星(原Ro 23-6240,AM-833)和环丙沙星制定的初始解释标准。所得结果表明,需对纸片扩散试验(5微克纸片)的标准进行如下修改:对于克林沙星,抑菌圈直径≥21毫米(≤1微克/毫升)为敏感,≤17毫米(≥4微克/毫升)为耐药;或抑菌圈直径≥19毫米(≤2微克/升)为敏感,≤15毫米(≥8微克/毫升)为耐药;对于氟罗沙星,抑菌圈直径≥16毫米(≤2微克/毫升)为敏感,≤11毫米(≥8微克/毫升)为耐药;对于环丙沙星,抑菌圈直径≤17毫米(≥4微克/毫升)为耐药。这些修改使标准化试验方法之间的总绝对解释准确性最大化,尤其是在检测真正耐药菌株时,将假敏感(极重大错误)的可能性降至最低。克林沙星对这些耐药菌株的抗菌谱最广,另外两种受试氟喹诺酮类药物(环丙沙星、氟罗沙星)的总体抗菌谱相当,尽管以重量计环丙沙星通常活性更强。我们敦促尽快采用这些标准,以提高广泛使用的美国国家临床实验室标准委员会纸片扩散试验方法的准确性。

相似文献

1
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.在使用一组耐环丙沙星临床分离株进行挑战研究后,对克林沙星(CI-960、AM-1091、PD127371)和氟罗沙星(Ro 23-6240、AM-833)的纸片扩散药敏试验标准的修改。
Diagn Microbiol Infect Dis. 1995 Apr;21(4):209-13. doi: 10.1016/0732-8893(94)00061-z.
2
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.使用环丙沙星耐药菌预测菌组对克林沙星与环丙沙星、氟罗沙星、氧氟沙星和司帕沙星进行交叉耐药性分析。
J Antimicrob Chemother. 1995 Aug;36(2):431-4. doi: 10.1093/jac/36.2.431.
3
Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.AM-1155与妥舒沙星和氟罗沙星对携带GyrA和ParC喹诺酮耐药性改变的淋病奈瑟菌临床分离株的体外抗菌活性比较。
Chemotherapy. 1997 Jul-Aug;43(4):239-44. doi: 10.1159/000239573.
4
Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.CI-960(PD127391,AM-1091)、氟罗沙星、洛美沙星和替马沙星对淋病奈瑟菌药敏试验的解释标准,包括在GC琼脂培养基中的药物稳定性。
J Clin Microbiol. 1992 May;30(5):1170-3. doi: 10.1128/jcm.30.5.1170-1173.1992.
5
Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.流感嗜血杆菌对CI-960、氟罗沙星和替马沙星药敏试验的解释标准。
Eur J Clin Microbiol Infect Dis. 1992 May;11(5):462-5. doi: 10.1007/BF01961865.
6
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.使用5微克纸片进行CI-960(AM-1091,PD127391)纸片扩散试验的解释标准。
Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):379-81. doi: 10.1016/0732-8893(92)90029-s.
7
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).对新型氟喹诺酮类药物DU-6859a与六种结构相似的化合物(环丙沙星、克林沙星、氟罗沙星、左氧氟沙星、氧氟沙星和司帕沙星)进行交叉耐药性分析。
Diagn Microbiol Infect Dis. 1995 Jan;21(1):51-4. doi: 10.1016/0732-8893(94)00116-e.
8
Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
Diagn Microbiol Infect Dis. 1995 Apr;21(4):227-30. doi: 10.1016/0732-8893(95)00047-e.
9
A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.氟罗沙星与其他三种喹诺酮类药物体外活性比较的多中心研究:来自27个中心的中期报告
Am J Med. 1993 Mar 22;94(3A):2S-8S.
10
Detection of quinolone-resistant Neisseria gonorrhoeae.耐喹诺酮淋病奈瑟菌的检测
J Clin Microbiol. 1996 Jun;34(6):1462-4. doi: 10.1128/jcm.34.6.1462-1464.1996.

引用本文的文献

1
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.克林沙星对来自北美10个中心的当代临床分离菌株的体外活性。
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
2
Initial clinical experience with clinafloxacin in the treatment of serious infections.克林沙星治疗严重感染的初步临床经验。
Drugs. 1995;49 Suppl 2:488-91. doi: 10.2165/00003495-199500492-00145.